REFERENCES
- Leitgeb C, Pecherstorfer M, Fritz E, Ludwig H. Quality of life in chronic anemia of cancer during treatment with recombinant human erythropoietin. Cancer 1994; 73: 2535–42.
- Rose E, Rai K, Revicki D, Brown R, Reblando J and the EPO in Anemia of CLL Study Group. Clinical and health status assessments in anemic chronic lymphocytic leukemia (CLL) patients treated with erythropoietin alfa (EPO). Blood 1994; 8 Suppl 1: 526 [Abstract].
- Glaspy J, Bukowski R, Steinberg D. Impact of therapy with erythropoietin alfa on clinical out-comes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. J Clin Oncol 1997; 15: 1218–34.
- Demetri DD, Kris M, Wade J, Degas L, Cella D. Quality-of-life benefit in chemotherapy patients treated with erythropoietin alfa is independent of disease response or tumor type: results from a prospective community oncology study. J Clin Oncol 1998; 16: 4312–25.
- Milbrink J, Birgegard G, Danersund A, Helmers C, Nordstrom L, Sandhagen B. Preoperative autolog-ous donation of 6 units of blood during rh-EPO treatment. Canad J Anaesth 1997; 44: 1315–18.
- Horina JH, Schwaberger G, Brussee H, Sauseng-Felleger G, Holzer H, Krejs GJ. Increased red cell 2,3-diphosphoglycerate levels in hemodialysis patients treated with erythropoietin. Nephrol Dialysis Transplant 1993; 8: 1219–22.
- Crowley JP, Chazan JA, Metzger JB, Pono LA, Valeri CR. Blood rheology and 2,3-diphospho-glycerate levels after erythropoietin treatment. Ann Clin Lab Sci 1993; 23: 24–32.